Health Discovery Corporation (OTCBB: HDVY) announced today that on
December 18, 2012, the Board of Directors appointed Dr. John Norris as
its new CEO. He succeeds Dr. Stephen Barnhill, who founded HDC, served
as Chairman and CEO for 9 years and brought the Company to profitability
in Q3 2012.
Dr. Norris, 65, until his appointment as CEO, was Executive Vice
President, Chief Technology Officer, and Chief Regulatory Officer of
Health Discovery Corporation and had served in that capacity for the
past three years.
"I look forward to assuming the role of CEO at Health Discovery
Corporation and leading the Company to its next level of success,"
stated John A. Norris, JD, MBA, Chief Executive Officer of Health
Discovery Corporation, "and I want to personally thank Dr. Stephen
Barnhill for his many years of dedication to and leadership of HDC as
Chairman and CEO from its inception through its profitability. I also
want to acknowledge his contribution as an inventor of some 40 of HDC's
patents which are valuable assets of the Company. I look forward to
receiving his guidance and advice as I transition into my role as CEO."
Dr. Norris is a Former Principal Deputy Commissioner (second-in-command)
and Chief Operating Officer (COO) of the US FDA (Food and Drug
Administration), where with Former FDA Commissioner, Dr. Frank Young, he
co-led the last major reform of the FDA. This work was performed under
the overall leadership of President Ronald Reagan, HHS Secretaries
Margaret Heckler and Dr. Otis Bowen, FDA Commissioner Dr. Frank Young,
Senator Orrin Hatch, and Congressman Paul Rogers.
Dr. Norris is a Former Director and Co-Leader of the turnaround of
Summit Technology (NASDAQ: BEAM), inventor of computer-driven
(semi-automated) laser eye surgery. The FDA approved Summit's version of
LASIK using the Summit Apex Plus Excimer Laser Workstation. Alcon
Laboratories Inc. (NYSE: ACL), the eye-products unit of Nestle, S.A.,
acquired Summit Technology, Inc., for $893 million. Summit Technology,
based in Waltham, Massachusetts, had sales of $111 million.
In addition, Dr. Norris is a Former Corporate Officer, Corporate
Executive Vice President, and Worldwide Managing Director for Life
Sciences Coaching and Consulting at Hill & Knowlton. With 83 offices in
46 countries, Hill and Knowlton is one of the world's largest marketing
and management coaching and consulting firms. It represents many of the
world's premier healthcare, life sciences, and healthcare-IT companies
Dr. Norris is a Director of Ischemix, a developer of next generation
heart medicines for advancing ischemia-reperfusion therapy. In addition,
he was CEO and is now Chairman of Needlebot, a developer and
manufacturer of a next generation software search engine for searching
and analyzing "unstructured text" contained in many sources, including
nurses' notes, doctors' notes, medical records, medical literature, and
clinical trial records, at both the Internet and Enterprise levels, as
well as CEO and now Chairman of Norris Capital, a corporate finance and
holding company and a boutique legal, regulatory, financial, marketing,
and management/strategy coaching and consulting firm. He is also a
Director of Last Call Ventures, LLC, a food-supplement company.
Dr. Norris was CEO and is now Chairman of FDDH (Food, Drug, Device, and
Healthcare), a healthcare-delivery and healthcare-IT coaching firm, and
was CEO and is now Chairman of the Joseph D. Norris, Esq., Health Law
and Public Policy Fund. The Joseph D. Norris, Esq., Health Law and
Public Policy Fund supports university scholarships for health law and
public policy student training.
Dr. Norris is also the Founder and Former Faculty-Editor-in-Chief and
CEO of the academic journal, The American Journal of Law and Medicine,
which he founded at Harvard, MIT, and Boston University, and which is
now housed at Boston University.
Dr. Norris is the Former Chairman of Global MedChoices, which is
developing a planned response to US healthcare reform at the convergence
of three elements: (1) advanced healthcare-IT, (2) specialty surgical
services, and (3) key medical tourism locations.
He is also a Former Chairman of the American Society of Law, Medicine,
and Ethics, a Former Vice-Chairman of the Massachusetts 4-H Foundation,
and a Former Vice-Chairman of the American Bar Association's (ABA)
Health Law Committee.
Dr. Norris has been a consultant to the senior management of global
companies, including: Pfizer, Merck, J&J, and Glaxo.
Dr. Norris received a BA in Economics, with minors in Political Science
and Chemical Engineering, from the University of Rochester (where he was
a two varsity-sport athlete, and became a member of the university's
Trustee's Council); a JD with emphasis in health law, corporate law, and
international law from Cornell University's Law School, where he was
Editor-in-Chief of The International Law Journal; an MBA with emphasis
in healthcare and healthcare-IT policy and management, from Cornell
University's S.C. Johnson Graduate School of Management; and a Graduate
Certificate from Harvard University's Kennedy School of Government. He
is also a Former Harvard faculty member, where he taught health policy
and management, including healthcare-IT reform,
healthcare-delivery-system reform, and FDA reform.
According to HDC Board Chairman, Dr. Joe McKenzie, "John has served with
distinction for the past three years, and we intend to rely on his
global vision of the future of healthcare-delivery-system reform, of
healthcare-IT reform, and of FDA reform to drive the transformation of
HDC into its next phase of growth."
HDC Director, Dr. Herb Fritsche stated, "I have known John for a long
time and have worked closely with him over the past three years. I can
attest to his impeccable personal integrity, intellectual honesty,
outstanding vision, and keen knowledge, insights, and judgment regarding
the future of advanced healthcare technology, healthcare-delivery-system
reform, healthcare-IT reform, and FDA reform. His strong business
reputation, and his exceptional advisory and executive capabilities, are
all well known to me."
HDC Director, Mr. Sumio Takeichi commented, "I have worked closely with
John for nearly 20 years, both on boards and in business ventures, and
I, too, can attest to his honesty, integrity, courage, insight, and
intelligence when under pressure. He has the best values, capabilities,
and experiences of anyone I know, for teasing potential out of HDC's
technologies and turning the Company's fortunes in a strongly positive
direction. His availability and his willingness to take on that
challenge are both God sends."
Dr. Stephen Barnhill, outgoing CEO, stated, "I have worked closely with
John off and on over the past 20 years and I admire John for his keen
vision, his prior successes, his comprehensive understanding of HDC's
technology and his business insights and contacts. He is the perfect
choice to succeed me, and I am absolutely committed to assisting him
with a smooth transition and supporting him in any way that I can to
bring success to HDC and its shareholders."
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that
uses advanced mathematical techniques to analyze large amounts of data
to uncover patterns that might otherwise be undetectable. It operates
primarily in the emerging field of personalized medicine where such
tools are critical to scientific discovery. Its primary business
consists of licensing its intellectual property and developing its own
product line of biomarker-based diagnostic tests that include human
genes and genetic variations, as well as gene, protein, and metabolic
expression differences and image analysis in digital pathology and
radiology. For more information, see www.healthdiscoverycorp.com.
This document contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, the accuracy of
which is necessarily subject to risks and uncertainties, including,
without limitation, statements regarding future performance,
opportunities and investments, and anticipated results in general. From
time to time the Company may make other forward-looking statements
relating to other matters, including without limitation,
commercialization plans and strategic partnerships. Actual results may
differ materially due to a variety of factors, including, among other
things, the acceptance of our approach to applying mathematics computer
science and physics into the disciplines of biology, organic chemistry
and medicine and our products and technologies associated with those
approaches, the ability to develop or commercialize new drugs, therapies
or other products based on our approaches, and other factors set forth
from time to time in the Company's Securities and Exchange Commission
All forward-looking statements and cautionary statements included in
this document are made as of the date hereof based on information
available to the Company as of the date hereof, and the Company assumes
no obligation to update any forward-looking statement or cautionary
[ Back To NFVZone's Homepage ]